|Podcasts|September 16, 2021
Episode 91: A New Way to Partner With Academia
Author(s)Elaine Quilici, Miranda Schmalfuhs
Dr. Michael Henderson, chief business officer of BridgeBio Pharma, and one of Pharm Exec’s 2021 Emerging Pharma Leaders, discusses how his company goes beyond the traditional “hand off” approach between academia and industry, and looks to partner with institutions early on to fill important voids in drug development.
Advertisement
Dr. Michael Henderson, Chief Business Officer of BridgeBio Pharma, talks about how his company is partnering with academia in a novel way to develop important programs that might otherwise be dropped.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Industry’s Communication and Engagement with FDA
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
4
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
5